Synergy Innovation Co., Ltd. (048870)

Overview

Synergy Innovation Co., Ltd., established in 1998 and based in Seongnam-Si, South Korea, operates in the healthcare sector with a focus on the research and development, as well as the investment in generic drugs, new pharmaceuticals, medical devices, and health functional foods. The company's activities span a broad spectrum of healthcare needs, from the production and sale of various culture media vital for hospitals, pharmaceuticals, and industries such as food and cosmetics, to the development of innovative medical solutions and devices. Moreover, Synergy Innovation is proactive in investing and developing technologies across different fields, including microbiology, bacteriology, and virology, underlining its commitment to advancing healthcare and medical research.

Products and Services

• Culture Media:

  Synergy Innovation produces and distributes a wide range of culture media, which are essential tools in medical, pharmaceutical, and biochemical laboratories for the cultivation of microorganisms, cells, and tissues. These products serve critical roles in hospitals, pharmaceutical research, and industries manufacturing food and cosmetics, facilitating the analysis and production of health-related products.

• Synergy Innovation – Universal Transport Solutions (SI-UTS):

  This proprietary technology constitutes a significant part of the company’s portfolio. The SI-UTS is designed to innovate the way biological samples are transported, ensuring their stability and integrity, which is crucial for accurate analysis and diagnostics in medical and research settings.

• Pharmaceutical Formulations:

  The company specializes in the development and commercialization of pharmaceutical formulations, focusing on the creation of generic drugs as well as the innovation of new therapeutic solutions. These efforts are aimed at addressing diverse health conditions, thereby contributing to public health and wellness.

• Non-Vascular Stents:

  Synergy Innovation is also engaged in the development of non-vascular stents, which are used to treat a variety of medical conditions outside the vascular system, such as in the gastrointestinal tract. These devices represent a critical segment of the company's medical device portfolio, providing important treatment options for patients.

• Investments in Microbiology, Bacteriology, and Virology:

  Reflecting its commitment to healthcare innovation, the company invests in research and development across various scientific fields, including microbiology, bacteriology, and virology. These investments are geared towards developing new medical technologies and products that can effectively combat diseases and improve patient care.